<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01077271</url>
  </required_header>
  <id_info>
    <org_study_id>P11-040</org_study_id>
    <nct_id>NCT01077271</nct_id>
  </id_info>
  <brief_title>Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA</brief_title>
  <official_title>PMOS to Evaluate the Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA Over 3 Consecutive Respiratory Syncytial Virus (RSV) Seasons in Austria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assign Data Management and Biostatistics GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against
      respiratory syncytial virus (RSV) infection as shown in the IMpact study. Many factors such
      as parents' knowledge of burden of respiratory syncytial virus disease or physicians'
      satisfaction with Synagis as well as the appropriate use of the product might influence
      compliance. The primary objective of this observational study is to evaluate the compliance
      to Synagis under daily pediatricians practice conditions in premature infants 33 to 35 weeks
      gestational age (wGA). Palivizumab, monoclonal antibody for passive immunoprophylaxis against
      severe respiratory syncytial virus disease, was administered according to usual clinical
      practice. Compliance was assessed using four criteria: The number of injections per
      participant per respiratory syncytial virus season, the body site where injections were
      administered, the interval in days between injections, and the dosage per administration.
      Originally the study was to include two respiratory syncytial virus seasons but was extended
      to a third season.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Injections Per Patient Per Season</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>The average number of injections administered per participant within a respiratory syncytial virus season.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Site of Injections Per Administration</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>The body site of injection administration for participants at each study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interval Between Administrations</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>The average number of days that elapsed between palivizumab injections administered at the previous study visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dosage Per Administration</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>The median dose and range of palivizumab (milligrams) that was administered at each study visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Pain During Injection According to Pain Scores (VAS and Modified Behavioral Pain Scale)</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>The clinician who administered the palivizumab injection was asked to rate pain during injection using a visual analog scale (VAS) and the Modified Behavior Pain Scale (MBPS) as published by Carbajal et al., 2008. The VAS ranged from 0 (no pain) to 100 (maximum pain). The Modified Behavioral Pain Scale ranged from 0 (no pain) to 10 (maximum pain) through the evaluation of 3 items: Facial expressions, cry, and movements. If more than one injection was given at a visit, then the first injection was rated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parents Knowledge of Burden of RSV Disease Via Interview by Physician</measure>
    <time_frame>One RSV season (5 months)</time_frame>
    <description>An informational brochure was given to parents of participants. Parents were interviewed by the treating physician at the first study visit (V1) and last study visit (LSV) (or early termination visit [ET]) for those participants discontinuing from the study). Parental knowledge of the burden of respiratory syncytial virus (RSV) disease was assessed using a questionnaire. Parents were considered to have &quot;good RSV awareness&quot; if all questions were answered and at least 3 of the 4 questions regarding the burden of RSV disease were answered correctly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness of Palivizumab at the End of the Observation Period is Checked by the Physician by Ranking in a Visible Analog Scale</measure>
    <time_frame>One RSV season (5 months), end of study</time_frame>
    <description>The therapeutic effect of palivizumab was assessed by the treating physician using a visual analog scale from 0 to 10, where 0 indicated that palivizumab did not match expectations at all and 10 indicated that palivizumab met all expectations. The physician rated palivizumab treatment for each participant at the last study visit (LSV) or, in the case of participants withdrawing from the study, at the early termination (ET) visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">124</enrollment>
  <condition>Premature Infants</condition>
  <arm_group>
    <arm_group_label>Premature infants 33 - 35 wGA prophylaxed with palivizumab</arm_group_label>
    <description>Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with Synagis (palivizumab)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Medical practices specialized in pediatrics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premature infant 33 to 35 weeks gestational age

          -  Younger than 3 months at respiratory syncytial virus season start

          -  At least 4 points according to the Austrian risk score according to Austrian
             guidelines: 1 point younger than 3 months (at start of respiratory syncytial virus
             season), 1 point neurologic disease, 1 point weight less than 10th percentile, 1 point
             discharge from hospital during respiratory syncytial virus season (1 Oct - 30 March),
             1 point older siblings, 0.5 points multiple births, 0.5 points day care attendance,
             0.5 points passive tobacco smoke exposure, 0.5 points socio-economic status
             (overcrowding)

          -  Synagis application (prescription)

          -  Signed authorization form for data use (parental authorization)

        Exclusion Criteria:

          -  Patients without Synagis prescription

          -  Patients who meet contraindications as outlined in the latest version of Synagis
             summary of product characteristics (SmPC):

               -  Patients with known hypersensitivity to palivizumab or any component of the
                  formulation or other humanized monoclonal antibodies

          -  Patients with chronic lung disease

          -  Patients with congenital heart disease

          -  Greater than 36 weeks gestational age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>1 Year</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Astrid Dworan-Timler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27772</name>
      <address>
        <city>Amstetten</city>
        <zip>3300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52871</name>
      <address>
        <city>Amstetten</city>
        <zip>3300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52873</name>
      <address>
        <city>Feldkirch</city>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40437</name>
      <address>
        <city>Ganserndorf</city>
        <zip>2230</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30843</name>
      <address>
        <city>Hollabrunn</city>
        <zip>2020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27767</name>
      <address>
        <city>Judenburg</city>
        <zip>8750</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27770</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27777</name>
      <address>
        <city>Klosterneuburg</city>
        <zip>3400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30842</name>
      <address>
        <city>Krems</city>
        <zip>3500</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27771</name>
      <address>
        <city>Leonding</city>
        <zip>4060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52867</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58943</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 18603</name>
      <address>
        <city>Linz</city>
        <zip>4030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40445</name>
      <address>
        <city>Linz</city>
        <zip>4040</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52874</name>
      <address>
        <city>Linz</city>
        <zip>4040</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52870</name>
      <address>
        <city>Mattersburg</city>
        <zip>7210</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 48262</name>
      <address>
        <city>Neufeld</city>
        <zip>2491</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27775</name>
      <address>
        <city>Purkersdorf</city>
        <zip>3002</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27765</name>
      <address>
        <city>Scheibbs</city>
        <zip>3270</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40440</name>
      <address>
        <city>Schorfling</city>
        <zip>4861</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30850</name>
      <address>
        <city>St Polten</city>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27764</name>
      <address>
        <city>Telfs</city>
        <zip>6410</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40439</name>
      <address>
        <city>Traisen</city>
        <zip>3160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30848</name>
      <address>
        <city>Tulln</city>
        <zip>3400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27776</name>
      <address>
        <city>Tulln</city>
        <zip>3430</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30845</name>
      <address>
        <city>Vienna</city>
        <zip>1020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30849</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40432</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40447</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27773</name>
      <address>
        <city>Vienna</city>
        <zip>1040</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52879</name>
      <address>
        <city>Vienna</city>
        <zip>1060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27769</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40446</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 52878</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27774</name>
      <address>
        <city>Vienna</city>
        <zip>1110</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27762</name>
      <address>
        <city>Vienna</city>
        <zip>1120</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 27763</name>
      <address>
        <city>Vienna</city>
        <zip>1150</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40442</name>
      <address>
        <city>Vienna</city>
        <zip>1190</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30851</name>
      <address>
        <city>Vienna</city>
        <zip>1200</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 58942</name>
      <address>
        <city>Vienna</city>
        <zip>1200</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30846</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30847</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57793</name>
      <address>
        <city>Vienna</city>
        <zip>1210</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 30852</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 40425</name>
      <address>
        <city>Vienna</city>
        <zip>1220</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2010</study_first_posted>
  <results_first_submitted>May 17, 2012</results_first_submitted>
  <results_first_submitted_qc>August 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2012</results_first_posted>
  <last_update_submitted>August 20, 2012</last_update_submitted>
  <last_update_submitted_qc>August 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Premature infants</keyword>
  <keyword>Respiratory Syncytial Virus (RSV)</keyword>
  <keyword>Compliance</keyword>
  <keyword>Palivizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palivizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Premature Infants 33 - 35 wGA Prophylaxed With Palivizumab</title>
          <description>Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with palivizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Treated With Palivizumab</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Number of Participants Analyzed</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parental desire</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failure, did not take palivizumab</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Quota used up (insurance reimb issue)</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Changed doctors</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Parents thought too many injections</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>End of RSV season nearly reached</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Mother unconvinced of the necessity</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RSV Season 1</title>
          <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
        </group>
        <group group_id="B2">
          <title>RSV Season 2</title>
          <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
        </group>
        <group group_id="B3">
          <title>RSV Season 3</title>
          <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
        </group>
        <group group_id="B4">
          <title>No Matching RSV Season</title>
          <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>The chronological age of participants at study entry.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than 1 and less than or equal to 2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 to 4.5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Age not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age</title>
          <description>The gestational age of participants at birth in week of gestation.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>23 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>33 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>34 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>35 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <description>The body weight of participants at the first study visit.</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.9" spread="1.4"/>
                    <measurement group_id="B2" value="3.8" spread="1.5"/>
                    <measurement group_id="B3" value="4.1" spread="1.6"/>
                    <measurement group_id="B4" value="3.5" spread="1.1"/>
                    <measurement group_id="B5" value="3.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Injections Per Patient Per Season</title>
        <description>The average number of injections administered per participant within a respiratory syncytial virus season.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>Participants who were administered palivizumab were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Injections Per Patient Per Season</title>
          <description>The average number of injections administered per participant within a respiratory syncytial virus season.</description>
          <population>Participants who were administered palivizumab were included in the analysis.</population>
          <units>Injections administered</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="1.3"/>
                    <measurement group_id="O2" value="3.9" spread="1.1"/>
                    <measurement group_id="O3" value="4.0" spread="1.4"/>
                    <measurement group_id="O4" value="1.0" spread="0.0"/>
                    <measurement group_id="O5" value="3.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Site of Injections Per Administration</title>
        <description>The body site of injection administration for participants at each study visit.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Body Site of Injections Per Administration</title>
          <description>The body site of injection administration for participants at each study visit.</description>
          <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3: Other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4: Other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5: Other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 6: Other location</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 7: Thigh</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Interval Between Administrations</title>
        <description>The average number of days that elapsed between palivizumab injections administered at the previous study visit.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1 (S1)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2 (S2)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3 (S3)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season (NS)</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Interval Between Administrations</title>
          <description>The average number of days that elapsed between palivizumab injections administered at the previous study visit.</description>
          <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V2 (S1 n=33; S2 n=42; S3 n=29; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="9.1"/>
                    <measurement group_id="O2" value="30.6" spread="9.2"/>
                    <measurement group_id="O3" value="28.6" spread="9.2"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="29.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3 (S1 n=32; S2 n=42; S3 n=24; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="12.4"/>
                    <measurement group_id="O2" value="34.7" spread="12.1"/>
                    <measurement group_id="O3" value="30.3" spread="4.8"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="33.1" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 (S1 n=20; S2 n=28; S3 n=23; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5" spread="9.4"/>
                    <measurement group_id="O2" value="41.8" spread="48.2"/>
                    <measurement group_id="O3" value="32.0" spread="5.5"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="36.6" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V5 (S1 n=15; S2 n=13; S3 n=16; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" spread="13.9"/>
                    <measurement group_id="O2" value="32.5" spread="12.9"/>
                    <measurement group_id="O3" value="28.4" spread="5.5"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="31.3" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V6 (S1 n=6; S2 n=3; S3 n=4; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.8" spread="10.3"/>
                    <measurement group_id="O2" value="30.0" spread="1.7"/>
                    <measurement group_id="O3" value="29.5" spread="1.7"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="27.5" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V7 (S1 n=2; S2 n=3; S3 n=0; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="0.0"/>
                    <measurement group_id="O2" value="30.0" spread="1.7"/>
                    <measurement group_id="O3" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="31.6" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Dosage Per Administration</title>
        <description>The median dose and range of palivizumab (milligrams) that was administered at each study visit.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1 (S1)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2 (S2)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3 (S3)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season (NS)</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Dosage Per Administration</title>
          <description>The median dose and range of palivizumab (milligrams) that was administered at each study visit.</description>
          <population>The analysis population includes participants who were administered palivizumab and had data available for the study visits listed.</population>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V1 (S1 n=36; S2 n=44; S3 n=26; NS n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" spread="1925.2" lower_limit="40.0" upper_limit="7500.0"/>
                    <measurement group_id="O2" value="50.0" spread="25.8" lower_limit="24.0" upper_limit="150.0"/>
                    <measurement group_id="O3" value="73.5" spread="26.2" lower_limit="30.0" upper_limit="125.0"/>
                    <measurement group_id="O4" value="52.5" spread="24.2" lower_limit="50.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="60.0" spread="1134.4" lower_limit="24.0" upper_limit="7500.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2 (S1 n=32; S2 n=43; S3 n=27; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="1210.7" lower_limit="50.0" upper_limit="5000.0"/>
                    <measurement group_id="O2" value="70.0" spread="23.2" lower_limit="50.0" upper_limit="150.0"/>
                    <measurement group_id="O3" value="84.0" spread="22.0" lower_limit="43.0" upper_limit="130.0"/>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="79.5" spread="686.0" lower_limit="43.0" upper_limit="5000.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3 (S1 n=29; S2 n=42; S3 n=21; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="3077.5" lower_limit="60.0" upper_limit="10000.0"/>
                    <measurement group_id="O2" value="80.0" spread="22.7" lower_limit="45.0" upper_limit="150.0"/>
                    <measurement group_id="O3" value="96.0" spread="21.1" lower_limit="58.0" upper_limit="140.0"/>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="85.5" spread="1795.8" lower_limit="45.0" upper_limit="10000.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 (S1 n=20; S2 n=28; S3 n=20; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" spread="1767.4" lower_limit="73.0" upper_limit="8000.0"/>
                    <measurement group_id="O2" value="97.5" spread="285.3" lower_limit="54.0" upper_limit="1600.0"/>
                    <measurement group_id="O3" value="100.0" spread="24.1" lower_limit="65.0" upper_limit="150.0"/>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="100.0" spread="973.1" lower_limit="54.0" upper_limit="8000.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V5 (S1 n=15; S2 n=13; S3 n=13; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="7.8" lower_limit="80.0" upper_limit="111.0"/>
                    <measurement group_id="O2" value="100.0" spread="18.2" lower_limit="80.0" upper_limit="150.0"/>
                    <measurement group_id="O3" value="100.0" spread="20.1" lower_limit="78.0" upper_limit="150.0"/>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="100.0" lower_limit="78.0" upper_limit="150.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V6 (S1 n=5; S2 n=3; S3 n=2; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="122" lower_limit="90.0" upper_limit="123.0"/>
                    <measurement group_id="O2" value="100.0" spread="17.3" lower_limit="100.0" upper_limit="130.0"/>
                    <measurement group_id="O3" value="101.0" spread="8.5" lower_limit="95.0" upper_limit="107.0"/>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="100.0" spread="12.5" lower_limit="90.0" upper_limit="130.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V7 (S1 n=2; S2 n=3; S3 n=0; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" spread="0" lower_limit="100.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O4" value="NA" spread="0">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="100.0" spread="0" lower_limit="100.0" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Pain During Injection According to Pain Scores (VAS and Modified Behavioral Pain Scale)</title>
        <description>The clinician who administered the palivizumab injection was asked to rate pain during injection using a visual analog scale (VAS) and the Modified Behavior Pain Scale (MBPS) as published by Carbajal et al., 2008. The VAS ranged from 0 (no pain) to 100 (maximum pain). The Modified Behavioral Pain Scale ranged from 0 (no pain) to 10 (maximum pain) through the evaluation of 3 items: Facial expressions, cry, and movements. If more than one injection was given at a visit, then the first injection was rated.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>The analysis included participants who were administered palivizumab and had data available for the study visits listed.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1 (S1)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2 (S2)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3 (S3)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season (NS)</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Pain During Injection According to Pain Scores (VAS and Modified Behavioral Pain Scale)</title>
          <description>The clinician who administered the palivizumab injection was asked to rate pain during injection using a visual analog scale (VAS) and the Modified Behavior Pain Scale (MBPS) as published by Carbajal et al., 2008. The VAS ranged from 0 (no pain) to 100 (maximum pain). The Modified Behavioral Pain Scale ranged from 0 (no pain) to 10 (maximum pain) through the evaluation of 3 items: Facial expressions, cry, and movements. If more than one injection was given at a visit, then the first injection was rated.</description>
          <population>The analysis included participants who were administered palivizumab and had data available for the study visits listed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>V1 VAS (S1 n=37; S2 n=43; S3 n=22; NS n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.2" spread="22.3"/>
                    <measurement group_id="O2" value="64.1" spread="19.5"/>
                    <measurement group_id="O3" value="53.5" spread="25.7"/>
                    <measurement group_id="O4" value="62.5" spread="9.6"/>
                    <measurement group_id="O5" value="57.0" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V1 MBPS (S1 n=37; S2 n=43; S3 n=29; NS n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.7"/>
                    <measurement group_id="O2" value="7.5" spread="1.5"/>
                    <measurement group_id="O3" value="6.9" spread="1.8"/>
                    <measurement group_id="O4" value="7.8" spread="1.5"/>
                    <measurement group_id="O5" value="7.2" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2 VAS (S1 n=33; S2 n=42; S3 n=25; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" spread="23.4"/>
                    <measurement group_id="O2" value="65.6" spread="18.2"/>
                    <measurement group_id="O3" value="57.2" spread="27.3"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="60.1" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V2 MBPS (S1 n=34; S2 n=42; S3 n=31; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="1.6"/>
                    <measurement group_id="O2" value="7.9" spread="1.5"/>
                    <measurement group_id="O3" value="7.3" spread="1.9"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="7.5" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3 VAS (S1 n=31; S2 n=41; S3 n=20; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="23.6"/>
                    <measurement group_id="O2" value="67.8" spread="16.4"/>
                    <measurement group_id="O3" value="60.0" spread="26.6"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="62.1" spread="21.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V3 MBPS (S1 n=31; S2 n=41; S3 n=24; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="1.5"/>
                    <measurement group_id="O2" value="7.9" spread="1.3"/>
                    <measurement group_id="O3" value="7.6" spread="1.8"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="7.7" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 VAS (S1 n=20; S2 n=28; S3 n=19; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.3" spread="24.5"/>
                    <measurement group_id="O2" value="66.3" spread="17.1"/>
                    <measurement group_id="O3" value="62.7" spread="23.5"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="63.5" spread="21.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V4 MBPS (S1 n=20; S2 n=28; S3 n=22; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="1.2"/>
                    <measurement group_id="O2" value="7.7" spread="1.4"/>
                    <measurement group_id="O3" value="7.4" spread="1.3"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="7.7" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V5 VAS (S1 n=15; S2 n=13; S3 n=14; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" spread="28.1"/>
                    <measurement group_id="O2" value="65.8" spread="13.2"/>
                    <measurement group_id="O3" value="64.4" spread="27.4"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="61.5" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V5 MBPS (S1 n=15; S2 n=13; S3 n=16; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="2.1"/>
                    <measurement group_id="O2" value="7.2" spread="1.4"/>
                    <measurement group_id="O3" value="8.2" spread="1.5"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="7.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V6 VAS (S1 n=5; S2 n=3; S3 n=4; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="31.2"/>
                    <measurement group_id="O2" value="78.3" spread="2.9"/>
                    <measurement group_id="O3" value="72.0" spread="34.3"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="64.9" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V6 MBPS (S1 n=5; S2 n=3; S3 n=4; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.2"/>
                    <measurement group_id="O2" value="7.3" spread="0.6"/>
                    <measurement group_id="O3" value="8.8" spread="1.9"/>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="7.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V7 VAS (S1 n=2; S2 n=3; S3 n=0; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" spread="0.0"/>
                    <measurement group_id="O2" value="73.3" spread="11.5"/>
                    <measurement group_id="O3" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="56.0" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>V7 MBPS (S1 n=2; S2 n=3; S3 n=0; NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="1.4"/>
                    <measurement group_id="O2" value="6.7" spread="1.2"/>
                    <measurement group_id="O3" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O4" value="NA">No data reported for this subgroup at this time point.</measurement>
                    <measurement group_id="O5" value="5.6" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parents Knowledge of Burden of RSV Disease Via Interview by Physician</title>
        <description>An informational brochure was given to parents of participants. Parents were interviewed by the treating physician at the first study visit (V1) and last study visit (LSV) (or early termination visit [ET]) for those participants discontinuing from the study). Parental knowledge of the burden of respiratory syncytial virus (RSV) disease was assessed using a questionnaire. Parents were considered to have “good RSV awareness&quot; if all questions were answered and at least 3 of the 4 questions regarding the burden of RSV disease were answered correctly.</description>
        <time_frame>One RSV season (5 months)</time_frame>
        <population>The analysis included parents of participants who were administered and had data available for the study visits listed.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1 (S1)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2 (S2)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3 (S3)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season (NS)</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Parents Knowledge of Burden of RSV Disease Via Interview by Physician</title>
          <description>An informational brochure was given to parents of participants. Parents were interviewed by the treating physician at the first study visit (V1) and last study visit (LSV) (or early termination visit [ET]) for those participants discontinuing from the study). Parental knowledge of the burden of respiratory syncytial virus (RSV) disease was assessed using a questionnaire. Parents were considered to have “good RSV awareness&quot; if all questions were answered and at least 3 of the 4 questions regarding the burden of RSV disease were answered correctly.</description>
          <population>The analysis included parents of participants who were administered and had data available for the study visits listed.</population>
          <units>Parents of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good RSV Awareness V1 (S1=39;S2=42;S3=32;NS=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good RSV Awareness LSV (S1=28;S2=32;S3=29;NS=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good RSV Awareness ET (S1=7;S2=8;S3=3;NS=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effectiveness of Palivizumab at the End of the Observation Period is Checked by the Physician by Ranking in a Visible Analog Scale</title>
        <description>The therapeutic effect of palivizumab was assessed by the treating physician using a visual analog scale from 0 to 10, where 0 indicated that palivizumab did not match expectations at all and 10 indicated that palivizumab met all expectations. The physician rated palivizumab treatment for each participant at the last study visit (LSV) or, in the case of participants withdrawing from the study, at the early termination (ET) visit.</description>
        <time_frame>One RSV season (5 months), end of study</time_frame>
        <population>The analysis included participants who were administered palivizumab and had data available for the study visits listed. A total of 100 participants were rated at the last study visit; 2 did not have ratings. A total of 18 participants who discontinued from the study were rated at the early termination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>RSV Season 1 (S1)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the first respiratory syncytial virus season (01 Nov 2008 through 31 March 2009)</description>
          </group>
          <group group_id="O2">
            <title>RSV Season 2 (S2)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the second respiratory syncytial virus season (01 Nov 2009 through 31 March 2010)</description>
          </group>
          <group group_id="O3">
            <title>RSV Season 3 (S3)</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab who were enrolled during the third respiratory syncytial virus season (01 Nov 2010 through 31 March 2011)</description>
          </group>
          <group group_id="O4">
            <title>No Matching RSV Season (NS)</title>
            <description>Premature infants 33 - 35 weeks gestational age whose palivizumab administration did not occur within Season 1, 2 or 3</description>
          </group>
          <group group_id="O5">
            <title>Total</title>
            <description>Premature infants 33 - 35 weeks gestational age prophylaxed with palivizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Palivizumab at the End of the Observation Period is Checked by the Physician by Ranking in a Visible Analog Scale</title>
          <description>The therapeutic effect of palivizumab was assessed by the treating physician using a visual analog scale from 0 to 10, where 0 indicated that palivizumab did not match expectations at all and 10 indicated that palivizumab met all expectations. The physician rated palivizumab treatment for each participant at the last study visit (LSV) or, in the case of participants withdrawing from the study, at the early termination (ET) visit.</description>
          <population>The analysis included participants who were administered palivizumab and had data available for the study visits listed. A total of 100 participants were rated at the last study visit; 2 did not have ratings. A total of 18 participants who discontinued from the study were rated at the early termination visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rating at LSV (S1 n=30;S2 n=36;S3 n=27;NS n=4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" spread="0.4"/>
                    <measurement group_id="O2" value="9.8" spread="0.6"/>
                    <measurement group_id="O3" value="9.9" spread="0.5"/>
                    <measurement group_id="O4" value="10.0" spread="0.0"/>
                    <measurement group_id="O5" value="9.9" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rating at ET visit (S1 n=7;S2 n=8;S3 n=3;NS n=0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="0.0"/>
                    <measurement group_id="O2" value="9.5" spread="0.9"/>
                    <measurement group_id="O3" value="10.0" spread="0.0"/>
                    <measurement group_id="O4" value="NA">No participants in this subgroup were rated at an early termination visit.</measurement>
                    <measurement group_id="O5" value="9.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were reported from the time informed consent was given until 90 days after the last dose of palivizumab. The average time from first to last study visit was approximately 125 days, with an average therapy duration of approximately 93 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Premature Infants 33 - 35 wGA Prophylaxed With Palivizumab</title>
          <description>Premature infants 33 - 35 weeks gestational age (wGA) prophylaxed with palivizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Abbott requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. Abbott requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if Abbott needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>Abbott</organization>
      <phone>1-800-633-9110</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

